This report studies RNA Interference (RNAi) Drug Delivery in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Metabolic disorders Alnylam Pharmaceuticals Inc Merck & Co. Inc Access Pharmaceuticals Inc Dicerna Pharmaceuticals Inc Calondo Pharmaceuticals Inc Marina Biotech Inc RXi Pharmaceuticals Corp Quark Pharmaceuticals Inc Silence Therapeutics plc Tacere Therapeutics Inc PhaseRx Inc Sirnaomics Inc Traversa Therapeutics Inc By types, the market can be split into Nanoparticle Drug Delivery Technology Pulmonary Drug Delivery Technology Nucleic Acid Drug Delivery Technology Aptamer Drug Delivery Technology By Application, the market can be split into Infectious Diseases Cardiology Oncology Neurology Ophthalmology Metabolic Disorders By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents Global RNA Interference (RNAi) Drug Delivery Market Professional Survey Report 2017 1 Industry Overview of RNA Interference (RNAi) Drug Delivery 1.1 Definition and Specifications of RNA Interference (RNAi) Drug Delivery 1.1.1 Definition of RNA Interference (RNAi) Drug Delivery 1.1.2 Specifications of RNA Interference (RNAi) Drug Delivery 1.2 Classi